Cybin Corp., a life-sciences company advancing psychedelic pharmaceuticals, has announced that Doug Drysdale has been appointed as CEO. With more than three decades of experience, Drysdale brings invaluable insight and expertise to his new role. In 2014 as a corporate director of a NASDAQ-listed pharmaceutical company, he led the company’s recapitalization efforts, raising an estimated $65 million. Consequently, he was appointment chairman and CEO and revamped the company’s management team and board of directors while also building a 220-person sales team — all within the first year. Ultimately he grew the company’s enterprise value exponentially from $80 million to around $800 million. In addition, as head of M&A at Actavis Group between 2004 and 2008, Drysdale led 15 corporate acquisitions across three continents along with raising approximately $3 billion of capital and managing lending syndicates, including over 25 banks, to fund growth. “With his myriad business accomplishments, Doug is the ideal leader for Cybin,” said Cybin co-founder and COO Paul Glavine in the press release. “We believe that his extensive health care sector background and international company management skills will help Cybin strengthen partnerships, develop strategic alliances and expand our international presence. We believe his strong leadership experience will help focus Cybin during our initial path to profitability.”
To view the full press release, visit http://ibn.fm/M1NoP
About Cybin Corp.
Cybin is a life-sciences company advancing mushroom-based psychedelic and nutraceutical products for various psychiatric and neurologic conditions. Cybin is developing technology that seeks to improve bioavailability to achieve the desired effects of psychedelics at lower dosages. Cybin is developing products with new delivery systems and intends to support clinical trials to evaluate efficacy to potentially combat major depressive disorder and addiction and improve cognitive flexibility. For more information about this company, please visit www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin
PsychedelicNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of PsychedelicNewsWire (PNW). NNB keeps you up-to-date on active US Public Companies complementary to PNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.
Please see full disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/